Literature DB >> 19052751

The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.

Khaled M Musallam, Thurayya Arayssi, Ali T Taher, Nadim Kanj, Imad Uthman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052751     DOI： 10.1007/s00296-008-0816-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  18 in total

1.  The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon.

Authors:  Imad Uthman; Kamel Mroueh; Thuraya Arayssi; Fuad Nasr; Abdul-Fattah Masri
Journal:  Semin Arthritis Rheum       Date:  2004-06       Impact factor: 5.532

2.  Refractory polymyositis responding to infliximab.

Authors:  I Uthman; J El-Sayad
Journal:  Rheumatology (Oxford)       Date:  2004-09       Impact factor: 7.580

3.  Infliximab as monotherapy in giant cell arteritis.

Authors:  Imad Uthman; Nadim Kanj; Samir Atweh
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

4.  Response of deep cutaneous vasculitis to infliximab.

Authors:  Imad W Uthman; Zahi Touma; Jinan Sayyad; Salah Salman
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

5.  Successful treatment of Sjogren's syndrome with rituximab.

Authors:  Z Touma; J Sayad; T Arayssi
Journal:  Scand J Rheumatol       Date:  2006 Jul-Aug       Impact factor: 3.641

6.  [Anti TNF-alpha treatment of a refractory polymyositis].

Authors:  D Wendling; C Prati; P Ornetti; E Toussirot; G Streit
Journal:  Rev Med Interne       Date:  2007-01-17       Impact factor: 0.728

7.  A novel therapeutic option in Cogan diseases? TNF-alpha blockers.

Authors:  M Fricker; A Baumann; F Wermelinger; P M Villiger; A Helbling
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

8.  Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case.

Authors:  Imad Uthman; Ali Taher; Ossama Abbas; Janine Menassa; Samer Ghosn
Journal:  Dermatology       Date:  2008-01-09       Impact factor: 5.366

9.  Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.

Authors:  L Josselin; A Mahr; P Cohen; C Pagnoux; G Guaydier-Souquières; G Hayem; C Job-Deslandre; F Liferman; J Pourrat; L Guillevin
Journal:  Ann Rheum Dis       Date:  2008-04-29       Impact factor: 19.103

10.  Cardiac sarcoidosis responding to monotherapy with infliximab.

Authors:  Imad Uthman; Zahi Touma; Maurice Khoury
Journal:  Clin Rheumatol       Date:  2007-03-30       Impact factor: 2.980
View more
  1 in total

1.  The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review.

Authors:  Vicky Nahra; Georges El Hasbani; Monique Chaaya; Imad Uthman
Journal:  Mediterr J Rheumatol       Date:  2020-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.